100442-49-7 Usage
Uses
Used in Pharmaceutical Industry:
5-(Chloromethyl)-3-(trifluoromethyl)-1,2,4-oxadiazole is used as a synthetic intermediate for the development of pharmaceutical compounds. Its unique structure allows for the creation of new drugs with potential therapeutic benefits.
Used in Agrochemical Industry:
In the agrochemical sector, 5-(Chloromethyl)-3-(trifluoromethyl)-1,2,4-oxadiazole is utilized as a building block in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Material Science:
5-(Chloromethyl)-3-(trifluoromethyl)-1,2,4-oxadiazole is employed as a component in the research and development of new materials. Its properties may contribute to advancements in areas such as polymers, coatings, and other material technologies.
While 5-(Chloromethyl)-3-(trifluoromethyl)-1,2,4-oxadiazole has shown promise in these areas, further research is necessary to fully explore its properties, understand its biological activity, and maximize its potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 100442-49-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,4,4 and 2 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 100442-49:
(8*1)+(7*0)+(6*0)+(5*4)+(4*4)+(3*2)+(2*4)+(1*9)=67
67 % 10 = 7
So 100442-49-7 is a valid CAS Registry Number.
100442-49-7Relevant academic research and scientific papers
MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO
-
Page/Page column 194, (2012/11/07)
The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.
